Mellozzan® (melatonin) approved in Turkey

EQL Pharma's key product Mellozzan® (tablets) has been approved for sale by the Turkish Medicines Agency. EQL's partner in Turkey, Abdi Ibrahim, will both manufacture and market Mellozzan® locally. Sales are expected to commence in the first half of 2026.

EQL receives a single-digit royalty based on sales.

Mellozzan® in Turkey is expected to be expanded with the oral solution in 2027. The application is currently under review by the Turkish Medicines Agency. Abdi Ibrahim has also submitted an application for approval of Mellozzan® (tablets and oral solution) in Kazakhstan.

About Mellozzan^®

Mellozzan® contains the sleep hormone melatonin and is indicated for children with ADHD and suffering from sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan® is also indicated for the short-term treatment of jet lag in adults.

About Abdi Ibrahim

Abdi Ibrahim Pharmaceuticals is Turkey's largest pharmaceutical company with 5,500 employees.